reboxetine has been researched along with am 251 in 1 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (am 251) | Trials (am 251) | Recent Studies (post-2010) (am 251) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 948 | 1 | 507 |
| Protein | Taxonomy | reboxetine (IC50) | am 251 (IC50) |
|---|---|---|---|
| Cannabinoid receptor 1 | Homo sapiens (human) | 0.0892 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Itakura, C; Katayama, M; Niimi, K; Takahashi, E | 1 |
1 other study(ies) available for reboxetine and am 251
| Article | Year |
|---|---|
Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Mice; Mice, Inbred CBA; Models, Animal; Morpholines; Motor Activity; Nomifensine; Piperidines; Pyrazoles; Reboxetine; Receptor, Cannabinoid, CB1; Rimonabant; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 2008 |